Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMN107 in Imatinib-Resistant/Intolerant CML and Ph+ ALL
NCT00109707Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2005
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 22
01
Overview
A Phase 2 trial of nilotinib in chronic myeloid leukemia (CML), Acute lymphoblastic leukemia, Philadelphia chromosome positive, hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), systemic mastocytosis (SM), sponsored by Novartis. Started Apr 2005; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)Acute lymphoblastic leukemia, Philadelphia chromosome positivehypereosinophilic syndrome (HES)chronic eosinophilic leukemia (CEL)systemic mastocytosis (SM)
Beyond the preview
Go deeper on NCT00109707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00109707.